Chen H, Zhang B, Yuan X, et al. Isoliquiritigenin-induced effects on Nrf2 mediated antioxidant defence in the HL-60 cell monocytic differentiation. Cell Biol Int. 2013 Nov;37(11):1215-1224. PMID: 23881796.
Wang Z, Wang N, Han S, et al. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PLoS One. 2013 Jul 5;8(7):e68566. PMID: 23861918.
Li Y, Zhao H, Wang Y, et al. Isoliquiritigenin induces growth inhibition and apoptosis through downregulating arachidonic acid metabolic network and the deactivation of PI3K/Akt in human breast cancer. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):37-48. PMID: 23747687.
Yuan X, Zhang B, Gan L, et al. Involvement of the mitochondrion-dependent and the endoplasmic reticulum stress-signaling pathways in isoliquiritigenin-induced apoptosis of HeLa cell. Biomed Environ Sci. 2013 Apr;26(4):268-76. PMID: 23534467.
Orlikova B, Schnekenburger M, Zloh M, et al. Natural chalcones as dual inhibitors of HDACs and NF-κB. Oncol Rep. 2012 Sep;28(3):797-805. PMID: 22710558.
Cho S, Kim S, Jin Z, et al. Isoliquiritigenin, a chalcone compound, is a positive allosteric modulator of GABAA receptors and shows hypnotic effects. Biochem Biophys Res Commun. 2011 Oct 7;413(4):637-42. PMID: 21945440.
Kawakami Z, Ikarashi Y, Kase Y. Isoliquiritigenin is a novel NMDA receptor antagonist in kampo medicine yokukansan. Cell Mol Neurobiol. 2011 Nov;31(8):1203-12. PMID: 21691759.